The Joint Interagency Task Force 401 (JIATF-401) announced today it has awarded a $5.2 million agreement to Perennial ...

Drug discovery requires two separate steps: checking whether a drug can bind to a harmful molecule or its receptor, and ...

LuxMare is a project completed this year by architecture office Mário Martins Atelier and which consists of two contemporary houses that complement one another while managing to maintain their ...

Vertex could have several catalysts in 2026, helping it set a strong foundation for the future. DexCom is expanding its addressable market in order to help deal with some current challenges. Neither ...

ETFs offer a convenient way for investors to gain broad, diversified exposure to stocks. It's hard to beat Vanguard's S&P 500 ETF, which has delivered excellent results over time. Vanguard's ...

(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...

(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...

Omeros Corporation has surged after out-licensing zaltenibart to Novo Nordisk, securing $340 million upfront and near-term milestones, with potential for $2.1 billion in additional payments. The deal ...

When he gets the ball, Brother Rice’s Jameson Davis creates a sound and fury all his own. The junior running back has a musician’s natural feel for rhythm and touch — how to build up a sense of joy, ...